Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clonidine for smoking cessation.

S G Gourlay1, L F Stead, N L Benowitz

  • 1Genentech Inc, 2 DNA Way, South San Francisco, CA 94080, USA. goo@gene.com

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Glioma: from genetic to cellular heterogeneity.

Frontiers in cell and developmental biology·2024
Same author

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.

The British journal of dermatology·2021
Same author

Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.

Clinical and experimental immunology·2019
Same author

Gender differences in the pharmacology of nicotine addiction.

Addiction biology·2016
Same author

Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers.

Clinical pharmacology and therapeutics·2014
Same author

Delayed bupropion cardiotoxicity associated with elevated serum concentrations of bupropion but not hydroxybupropion.

Clinical toxicology (Philadelphia, Pa.)·2013
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Clonidine may help smokers quit by reducing withdrawal symptoms. However, side effects like dry mouth and sedation can limit its usefulness for smoking cessation.

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Clinical Trials

Background:

  • Clonidine, initially developed for hypertension, acts on the central nervous system.
  • It has shown potential in mitigating withdrawal symptoms associated with various addictive behaviors, including smoking.

Purpose of the Study:

  • To evaluate the efficacy of clonidine as a smoking cessation aid.
  • To synthesize evidence from randomized controlled trials on clonidine's effectiveness in helping smokers quit.

Main Methods:

  • Systematic search of the Cochrane Tobacco Addiction Group trials register (up to October 1998).
  • Inclusion of randomized trials comparing clonidine to placebo for smoking cessation, with follow-up of at least 12 weeks.
  • Data extraction on trial characteristics and outcomes, with meta-analysis using a fixed-effects model where appropriate.

Related Experiment Videos

Main Results:

  • Six trials (three oral, three transdermal) met the inclusion criteria; five included behavioral counseling.
  • Clonidine demonstrated a statistically significant effect in promoting smoking cessation, with a pooled odds ratio of 1.89 (95% CI 1.30 to 2.74).
  • Common dose-dependent side effects included dry mouth and sedation.

Conclusions:

  • Clonidine appears effective in aiding smoking cessation, based on a limited number of trials with potential biases.
  • Significant side effects associated with clonidine use may restrict its practical application in smoking cessation programs.